Aah VI, a novel, N-glycosylated anti-insect toxin from Androctonus australis hector scorpion venom: isolation, characterisation, and glycan structure determination  by Hassani, O et al.
Aah VI, a novel, N-glycosylated anti-insect toxin from
Androctonus australis hector scorpion venom: isolation, characterisation,
and glycan structure determination
O. Hassania, D. Loewb, A. Van Dorsselaer1;b, M.J. PapandreŁoua, O. Sorokineb, H. Rochata,
F. Sampieria, P. Mansuellea
aUMR 6560, UniversiteŁ de la MeŁditerraneŁe CNRS, Laboratoire de Biochimie, IngeŁnierie des ProteŁines, IFR Jean Roche,
FaculteŁ de MeŁdecine Secteur Nord, Bd P. Dramard, 13916 Marseille Cedex 20, France
bUMR 7509, Laboratoire de SpectromeŁtrie de Masse Bio-Organique associeŁ au CNRS, UniversiteŁ Louis Pasteur,
1 rue B. Pascal, 67008 Strasbourg, France
Received 21 October 1998; received in revised form 10 December 1998
Abstract Aah VI was isolated from the venom of the North
African scorpion, Androctonus australis hector. It is the first
glycosylated neurotoxin from scorpion venom to be described. It
was not toxic to mice, when injected intracerebroventricularly at
a dose of 1.2 Wg per animal. However, it had typical activity in
Blatella germanica cockroaches resulting in gradual paralysis
and very low toxicity (LD50 = 8.5 Wg/g of animal). It consists of
66 amino acid residues and is heterogeneously N-glycosylated at
a single site, on asparagine 9, of the Asn-Gly-Thr sequence. The
potential N-glycosylation site was deduced from automatic
Edman degradation and amino acid analysis, and glycan
heterogeneity was evidenced by ESMS. Determination of the
N-glycan structures (dHex, Hex and HexNAc) was assessed by
nanoESMS/MS with picomolar amounts of sample. Current
knowledge of N-glycan structure and composition suggests that
the glycan structures are derived from a common core.
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1. Introduction
Na channels generating nerve impulses are the target of
the small polypeptide neurotoxins that are the very active
components of scorpion venoms. These toxins have been use-
ful as probes in Na channel structure and function studies.
They form a homologous family of mostly basic 60^70 residue
proteins [1,2] and consist of a single chain cross-linked by four
disulphide bridges [3,4]. Alignment of the eight half-cystine
residues of these toxins demonstrates their sequence similar-
ities and has made it possible to classify the toxins into several
structural groups of maximal similarity. The toxins may also
be classi¢ed as mammal-selective or insect-selective [5,6]. Gly-
cosylated scorpion neurotoxins have not previously been re-
ported.
We report here the puri¢cation and characterisation of the
¢rst glycosylated scorpion neurotoxin to be described: Aah
VI. It is an anti-insect toxin, isolated from the venom of the
Old World scorpion species Androctonus australis hector, and
is weakly active on insects. It bears some unusual glycan
structures and the possible function of these new structural
features is discussed. We also demonstrate the e⁄ciency of
analytical mass spectrometry, and particularly nanoESMS/
MS, for detecting protein heterogeneity and determining gly-
can structure in picomolar amounts of sample.
2. Materials and methods
2.1. Isolation and protein puri¢cation
Venom was obtained from Androctonus australis hector scorpions
by electrical stimulation of animals collected in the Hazoua area (Tu-
nisia). Partial puri¢cation was carried out in part as previously de-
scribed [5,7]. Then, the lyophilised RIT fraction [5] was loaded onto a
(7.5U75 mm) TosoHaas CM-5PW TSK column equilibrated with A
(20 mM NH4CH3COO, pH 4.7), and eluted at a £ow rate of 1 ml/min
with a gradient of 0^50% of B (500 mM NH4CH3COO, pH 6.8) in A
over 50 min. A sample of the fraction eluted at 22 min and was loaded
onto a LiChrospher 100 RP-8, 125U4 mm column (Merck), equili-
brated with 10% B (0.1% TFA in CH3CN), and eluted with a gradient
of 10^60% B in A (0.1% TFA in H2O) over 25 min.
2.2. Determination of toxicity in vivo
For all injections, the solution used was 0.15 M NaCl containing
2 mg bovine serum albumin (BSA) per ml.
Toxicity in male C57BL/6 black mice (20 þ 2 g) was tested by ICV
injection of 5 Wl of the solutions, and the LD50 was determined by a
lethality test 24 h after injection. Toxicity in male cockroaches (90^
110 mg) Blatella germanica was tested by injection of 1 Wl of the
solutions into the abdominal segment and the LD50 was determined
6 h after injection.
2.3. Enzymatic cleavage separation conditions, amino acid analyses and
automated degradation of protein or peptides
These procedures were essentially performed as previously de-
scribed [8]. Brie£y, Aah VI was reduced and either S-carboxymethyl-
ated (RCM) or S-pyridyl-ethylated (RPE), then desalted on a C8 RP
column and lyophilised. 3 nmol of RPE Aah VI was digested with
trypsin (3% (w/w), in 125 mM HCO3NH4, pH 8.5, 20 h, 37‡C). 5 nmol
of RCM protein was digested with chymotrypsin (5% (w/w), in
100 mM Tris-HCl, 10 mM CaCl2, pH 7.8, 20 h, 37‡C). 200 pmol of
RPE Aah VI was digested with Lys-C endoproteinase (4% (w/w), in
100 mM Tris-HCl, 10 mM CaCl2, pH 8.3, 4 h, 37‡C). The elution
gradient for tryptic or chymotryptic peptide separation was from 2%
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to 88% of solvent B (0.1% TFA in CH3CN/H2O, 70/30) in A (0.1%
TFA in H2O) over 60 min at 200 Wl/min on a 140 HPLC system
equipped with a C18 PTH column (2.1U220 mm, 5 Wm) from Applied
Biosystems, a Division of Perkin Elmer (Foster City, CA). For Lys-C
digest separation conditions, see Section 2.5. Detection was at 215 nm.
Puri¢ed peptides and protein were lyophilised. Aliquots of resus-
pended lyophilisate were used for sequencing with an Applied Bio-
systems 476 A sequencer. Other aliquots were used for amino acid
analysis on a Beckman 6300 apparatus [8]. Amino acid composition
was calculated as follows: experimental values are means of four
analyses, two after 20 h of hydrolysis, and the other two after 70 h,
except for Ser, Thr, Tyr and Cys, for which the values were obtained
by extrapolation to zero time hydrolysis, and for hydrophobic resi-
dues, for which the values after 70 h of hydrolysis were used. Trp was
determined spectrophotometrically.
2.4. Electrospray (ES) and nanoelectrospray mass spectrometry
(nanoESMS)
ES and nanoES mass spectra were obtained on a Quattro II mass
spectrometer (Micromass Ltd UK, Altrincham, UK). The nanoES
and ES drying gases were heated to 50‡C and 80‡C, respectively.
NanoES was performed with a modi¢ed probe as described [9] and
with no counter electrode. Samples were dissolved in H2O/CH3CN
(1/1) containing 1% formic acid, and then introduced into the electro-
spray ion source. The very low £ow rate (20 nmol/min) used in nano-
ESMS experiments allowed long analysis times (about 3 h on a sam-
ple of 4 Wl) and then multiple measurements, i.e optimisation of
fragmentation conditions, and adjustment of resolution.
2.5. Liquid chromatography mass spectrometry (LC-MS) and speci¢c
glycoside detection by single ion recording (SIR) of the Lys-C
digest of RPE Aah VI
LC-MS was performed as previously described [10] by coupling the
HPLC system described above to the ES mass spectrometer. The
separation on the narrow-bore column (2 mmU125 mm) was £ow-
split via a stainless steel Valco tee (Supelco, Saint-Germain-en-Laye,
France) with approximately 1/15 of column e¥uent being directed
towards the mass spectrometer via a fused silica capillary. The sam-
ples were separated on a Macherey Nagel Nucleosil 300-5 C18 column
(2 mmU125 mm) with a gradient of 0^60% of B (0.08% TFA in
CH3CN) in A (0.1% TFA in H2O) over 60 min, at 250 Wl/min. Total
ion current (TIC) trace (m/z 300^1800) and single ion recording (SIR)
were carried out by the stepped cone voltage technique from 50 to
90 V with an interscan delay of 0.1 s. Speci¢c oligosaccharides were
detected by scanning the oxonium ions and their water loss peaks [11]
(168 for (HexNAc-(H2O)2), 204 for (HexNAc), 274 for (NeuAc-
H2O), 292 for (NeuAc) and 366 for (Hex+HexNAc)), during ac-
quisition at a cone voltage of 90 V and 0.08 s duration for each
speci¢c mass.
2.6. Tandem mass spectrometry (MS/MS)
Native Aah VI, and the glycosylated peptide obtained by action of
Lys-C endoproteinase, were subjected to nanoES tandem mass spec-
trometry. The parent ions were selected in the ¢rst quadrupole mass
analyser and fragmented by collision-induced dissociation (CID) with
argon. The collision energy was adjusted for each selected ion so that
fragmentation was just apparent.
3. Results
3.1. Puri¢cation of Aah VI
Aah VI was puri¢ed by two chromatography steps. The
¢rst, which involved recycling gel ¢ltration on Sephadex
G-50, gave a similar pattern to that previously described [7],
with three major fractions (RIT, RI and RII) obtained (not
shown). Fraction RIT contains the insect-selective toxin Aah
IT [5]. Fraction RI contains the anti-mammal toxins Aah I
and Aah III and fraction RII contains the anti-mammal toxin
Aah II and the anti-crustacean toxin, Aah CT [12]. The RIT
fraction was further puri¢ed by cation-exchange chromatog-
raphy using a CM-TSK column, giving several fractions. The
fraction eluted at 22 min (Aah VI, Fig. 1A) produced a single
peak in analytical C8 HPLC (Fig. 1B) and accounted for 16%
of the absorbance at 280 nm of the insect toxin fraction.
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Fig. 1. Puri¢cation steps, and sequence determination and comparison. A: CM MemSep chromatography of the RIT fraction from recycling
chromatography. B: RP-HPLC of the Aah VI fraction from CM MemSep. Details are given in Section 2. C: Amino acid sequencing of Aah
VI. (a) Results of Edman degradation of RPE-Aah VI (_: unidenti¢ed residues); (b) chymotryptic peptide; (c) tryptic peptide; (d) complete se-
quence of Aah VI as deduced from a^c. The star indicates the glycosylated Asn residue. D: Sequence comparison with alignment of the half-
cystine residues. The sequences were taken from references [4,16^20]. n: glycosylated asparagine residue.
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3.2. Homogeneity tests
The amino acid composition of Aah VI was calculated from
amino acid analysis and spectrophotometric measurements.
Values for most of the residues, other than hydrolysis time-
sensitive residues, were close to integers: Asp 8.7; Thr 3.1; Ser
4.1; Glu 3.1; Pro 2.4; Gly 7.9; Ala 3.2; Cys 7.5; Val 3.7; Ile
2.0; Leu 2.3; Tyr 7.8; Phe 1.2; Lys 5.8; Trp 1; Arg 2.1. The
homogeneity of the protein was veri¢ed by C8 RP HPLC,
which gave a single peak (Fig. 1B), and by Edman degrada-
tion. We sequenced 400 pmol of native protein, and detected a
single PTH in each of the ¢rst 14 cycles, except in cycles 9 and
13 which gave no PTH (not shown). Position 13 may be
occupied by a conserved half-cystine residue, but position 9
has never been reported to correspond to such a residue in
other toxins.
The nanoES mass spectrum of native Aah VI showed sev-
eral series of multiply charged ions, demonstrating protein
heterogeneity. Fig. 2a shows the ions with seven charges.
The molecular masses of the nine main compounds (A^I)
were separated by þ 146 Da, þ 162 or þ 203 Da, typically
corresponding to dHex, Hex and HexNAc moieties, respec-
tively (Fig. 2a, inset).
3.3. Biological activity of Aah VI
Aah VI was completely inactive against mice, even when
1.2 Wg was injected ICV. In cockroaches, however, Aah VI
caused a very slow, gradual paralysis, but was not very toxic
(LD50 = 8.5 Wg/g of animal).
3.4. Sequence determination
We sequenced 700 pmol of RPE-Aah VI [8], and the N-
terminal amino acid residues were assigned, up to residue 55,
except for positions 9, 47, 52 and 53 (Fig. 1C, a). Two sets of
peptides were generated by enzymatic digestion to ¢ll these
gaps and complete the sequence. Chymotryptic peptide 47^57
(Fig. 1C, b) and the C-terminal tryptic peptide 56^66 (Fig. 1C,
c) were both useful. We therefore obtained the required level
of peptide overlap (Fig. 1C, a^c) to assign the sequence of the
alkylated protein entirely, except for the residue in position 9,
as shown in Fig. 1C, d.
After reduction and alkylation, the measured mass of the
major component A was 9212.3 Da (not shown), i.e. an in-
crease of 849.4 Da, in good agreement with the addition of
pyridylethyl moieties on the half-cystine residues of a protein
with four disulphide bridges (expected increase: 849.17 Da).
3.5. A single glycosylation site: assumption and demonstration
We compared the Aah VI amino acid composition deduced
by peptide sequencing with that obtained by acidic hydrolysis.
There was clearly an Asp residue missing in the sequence data,
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Fig. 2. Nanoelectrospray and/or nanoelectrospray tandem mass spectra obtained on intact Aah VI or peptide 9^14. a: NanoESMS of the seven
charged states of AahVI. Adducts of Na and K were observed. Numbers in parentheses indicate real masses. Inset: mass di¡erences between
the indicated forms. b: NanoESMS/MS of seven charged ion at m/z = 1120 (underlined), i.e. form E in panel a. Two deoxyhexoses have clearly
been lost, in succession, from the ¢rst N-acetylhexosamine, which is directly attached to the peptide backbone. c: NanoESMS/MS of seven
charged ion at m/z = 1242 (underlined), i.e. form F in panel a. The successive loss of hexoses and deoxyhexoses is observed. The observed frag-
ments are consistent with a trimannosylated core and two deoxyhexoses. d: NanoESMS/MS of the double charged ion at m/z = 882.9 (under-
lined), a glycoform of the Lys-C peptide (9^14), i.e. measured mass = 1763.6 (Table 1). Sequence ions are designated according to the usual no-
menclature [32,33]. The complete structure of the glycans can be deduced from the fragments observed. The ion at m/z = 741.7 (labelled with a
star) corresponds to the (M+H) of the core peptide (9^14).
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suggesting that the unidenti¢ed residue at position 9 was a
derivative of Asp or Asn converted back to Asp by acidic
hydrolysis. If residue 9 were Asn, the sequence NGT (posi-
tions 9^11) would be a genuine glycosylation site [13,14]. This
suggested that the heterogeneity was due to heterogeneous N-
glycan structures, linked to the Asn-9 residue only. Assuming
that residue 9 is indeed an Asn residue, the di¡erences be-
tween the theoretical mass of the polypeptide (7340.2 Da)
and the masses observed in the spectrum for the native protein
can be used to suggest a glycan composition for each glyco-
form of Aah VI, taking into account the oligosaccharide
structures of known N-linked glycans [15]. Using the two
lightest forms I and E as bases (excess mass = 552 and 495
Da, respectively), a composition may be suggested for form E
(HexNAc(dHex)2), and then for each form A^I, with
(HexNAc)2(dHex)2(Hex)4 for form F.
LC-MS with speci¢c detection of glycan residues (SIR) of
alkylated Aah VI digested with the Lys-C endoproteinase (not
shown) unambiguously showed that only one peptide
(RT = 24.88 min) was glycosylated. Data are shown in
Table 1 (columns 1 and 2). The mass spectrum of the glyco-
sylated peptide fraction had signals for three compounds (col-
umn 2, ¢rst three rows), whereas the other spectra had only
one. The fourth column indicates that the measured (column
2) and calculated (column 3) masses of the Lys-C peptides
were similar, except for the 9^14 peptide. The three com-
pounds in the peak at RT = 24.88 min are glycosylated forms
of the core peptide 9^14 with an Asn residue in position 9,
thus the mass di¡erences (column 4, a, b, c) correspond to
N-glycan moieties. These values are perfectly consistent with
the excess mass of three of the main glycosylated forms of the
native protein: A, G and B (Fig. 2a). The suggested glycan
compositions are given in column 5. Thus, these results clearly
demonstrate that Asn 9 was t-e only site of heterogeneous
carbohydrate chain attachment.
3.6. Determination of the N-glycan structures by nanoES
tandem mass spectrometry
A series of MS/MS experiments was performed for the most
intense series of multiply charged ions of the various glyco-
forms (A^I) observed on the native protein and also for a
series of very minor peaks. The spectra obtained all had reg-
ular and successive losses of 162, 146 or 204 Da from the
parent ions, due to the losses of a Hex, a dHex or a
(HexNAc), respectively. Fig. 2b,c shows the fragmentation
pattern and glycoform assignment based on the correlation of
the ions with the smallest and the largest values of m/z, i.e.
forms E and F. The analyses of these ions at m/z 1120.6 and
m/z 1242.4 located the two dHex residues on the inner Hex-
NAc (Fig. 2b) and the hexoses on the outer HexNAc (Fig.
2c). MS/MS analysis was also carried out for the major dou-
bly charged ion at m/z = 882.9 (Fig. 2d) of the glycopeptide 9^
14 (see Table 1, ¢rst line). The nanoESMS/MS analysis of this
ion showed that the dHex moieties were linked to the Hex-
NAc which was directly attached to the polypeptide chain
and, that the two HexNAc are bound together. The mass of
the core peptide was also detected at m/z = 741.7 correspond-
ing to (M+H) of the peptide. The structures of the various
glycoforms, A^I, are shown in Fig. 3a.
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Fig. 3. Glycoforms carried by Aah VI. a: Structures determined by
nanoESMS and nanoESMS/MS experiments, in order of increasing
molecular weight from left to right. W : dHex, a : Hex and E : Hex-
NAc. b: Suggested probable common glycan structure of three of
the main glycoforms, A, B and C. This speculation is based on (i)
the determined linkages between hexoses, deoxyhexoses and N-ace-
tylhexosamines for the various forms, as shown in panel a, (ii) in-
formation obtained from a series of attempts at deglycosylation,
which demonstrated the presence of structures with high mannose
content, and (iii) knowledge of the glycan biosynthetic pathways.
Table 1
Data from LC-MS, and suggested assignment of the peptides obtained from LC of the RPE Aah VI, digested with Lys-C endoproteinase
Data from LC-MS of
Lys-C-digested Aah VI
Data from sequence Mass di¡erence Proposed components of fractions from LC-MS
of Lys-C-digested Aah VI
RT (min) Meas. mass (Da) Calc. mass (Da)
24.88 1763.6 740.8 (9^14) 1022.8a 9^14+(HexNAc)2(dHex)2(Hex)2
24.88 1617.4 740.8 (9^14) 876.6b 9^14+(HexNAc)2(dHex)1(Hex)2
24.88 1925.8 740.8 (9^14) 1185.0c 9^14+(HexNAc)2(dHex)2(Hex)3
28.62 893.0 893.0 (1^8) 0.0 1^8
29.83 1285.6 1285.3 (56^66) 0.3 56^66
33.57 2259.5 2259.6 (15^31) 0.3 15^31
38.74 2484.7 2484.8 (37^55) 0.1 37^55
Two expected short peptides (32^33, 34^36) were not detected and were presumably eluted in the void volume.
First column: retention time for each individual compound; second column: measured mass of each compound; third column: calculated mass for
the corresponding expected core peptide (indicated in parentheses), deduced from sequence data (Fig. 1C) and Lys-C endoproteinase speci¢city;
fourth column: di¡erence between the measured and calculated masses. The di¡erences between the measured masses of glycoforms A, G and B,
and the calculated mass of the core protein were the same as in a, b and c, respectively; ¢fth column: proposed assignment of the compounds
(peptide residue range and glycan composition).
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4. Discussion
HPLC techniques are continually improving and it is now
possible to isolate minor fractions, with little or no pharma-
cological activity, from scorpion venoms. The Aah VI fraction
was not identi¢ed by its anti-insect activity, but was isolated
because it was eluted in the same gel ¢ltration fraction as the
contraction-causing insect-selective toxin Aah IT1 [5]. Amino
acid composition determinations and automatic N-terminal
sequencing of the native protein are e¡ective for testing the
core protein homogeneity, but are not appropriate for detect-
ing glycan heterogeneity because isoforms have identical chro-
matographic properties. We used analytical mass spectrome-
try to show glycan heterogeneity of Aah VI. With this
technique, we also demonstrated that Aah VI was reticulated
by four disulphide bridges.
Toxicity tests on cockroaches strongly suggest that the very
low anti-insect activity of Aah VI was not due to contaminat-
ing Aah IT1. If the contamination of Aah VI were 1/1000
(Aah IT1 LD50 = 10 ng/g, i.e. 850 times less than Aah VI),
the amount of Aah IT1 injected in the Aah VI LD50 dose
would have been close to the Aah IT1 LD50 and should
have led to an immediate paralysis (5^10 s for Aah IT1). If
there was less contamination, a lower lethality, but still an
immediate paralysis e¡ect, should have been observed, where-
as the Aah VI-induced paralysis took about 1 h.
Aah VI has amino acid sequence motifs that are conserved
in mammal-selective and insect-selective toxins, but its overall
sequence is signi¢cantly di¡erent from both these well-de¢ned
groups. Its sequence di¡ers extensively (Fig. 1D) from the
sequences of the excitatory anti-insect toxins Aah IT1 [4]
and Lqq IT1 [16]. It also di¡ers from Lqh KIT [17] and
Lqq III [18] (anti-insect K-toxin group), which are active
against both mammals and insects. It di¡ers to a lesser extent
from the sequences of two depressant anti-insect toxins Lqq
IT2 [16] and Lqh IT2 [19]. Remarkably, Aah VI is very sim-
ilar in sequence to Aah STR1 (Fig. 1D), a non-glycosylated
anatoxin puri¢ed from the venom of the same Old World
species (Mansuelle et al., unpublished results), the overall
folding of which is typical of toxins from the New World [20].
By use of NanoESMS and nanoESMS/MS, we succeeded in
identifying the glycan motifs of the isoforms from only a few
picomoles of sample. We used a very low £ow rate
(6 20 nmol/min), which made it possible to optimise fragmen-
tation for nanoESMS/MS using very small volumes (3 Wl) and
amounts of material (concentration of glycopeptide 9^14 was
about 1 pmol/Wl). This is very much less than the amount of
sample needed for 1H-NMR analysis, which is about 50 Wg of
glycans, i.e about 70 nmol of Aah toxin VI, although
1H-NMR gives much more complete information. Indeed,
the most striking feature of Aah VI is that various glycan
moieties are attached to it, increasing its molecular mass to
8500 Da and resulting in eluting from gel ¢ltration among the
long (70 residues) insect-selective neurotoxins. It cannot be
excluded that some of the observed multiple glycosylated
forms may result from the puri¢cation process, but in a recent
study to identify the origin of glycan heterogeneity of an
antibacterial peptide [21], we demonstrated that this hetero-
geneity was already present during the biosynthesis of the
peptide.
Mass spectrometry detected a diversity of short N-glycan
structures from Hex4(HexNAc)2dHex2 to HexNAc(dHex)2.
These data and current knowledge of glycosylation bio-
synthesis suggest that the common glycan core structure of
Aah VI is Asn-GlcNAc(K1-6Fuc)(K1-3Fuc)(L1-4GlcNAc).
This sequence is consistent with (i) Aah VI glycans being
partially sensitive to endoglycosidase F treatment (not
shown), which cleaves the L1-4 linkage between the two inner-
most N-acetylglucosamine residues [22] and (ii) reports of
such difucosylated structures for a phospholipase from honey
bee venom [23]. ManK1-6ManL1-4GlcNAcL1-4GlcNAc has
been isolated from honey bee venom glycoprotein [23] and
from normal human blood mononuclear cell interleukin-6
[24]. Given this and what is known of N-glycan structures,
the hexose residues of Aah VI glycans are probably mannose
residues, which typically form a branched antenna on the di-
N-acetylglucosaminyl core next to Asn (Fig. 3b). Thus, the
glycosylation pathway in scorpion cells is very di¡erent
from that in mammals, insects and plants [25^27]. There are
at least two possible reasons for the presence of such un-
usually short N-glycan structures: (i) an original glycosylation
pathway involving the sequential addition of various carbohy-
drates to the conserved glycosylation site (AsnXSer/Thr), as in
O-linked glycan biosynthesis, or (ii) high glycosidase activi-
ties extensively shortening the usual N-glycans to a
GlcNAcFuc2 structure. A similar degradation of mature
N-linked structures has been described in insect cells, in which
high levels of L-N-acetylgalactosaminidase and L-N-acetylglu-
cosaminidase activity may be responsible for the extensive
shortening of complex glycans to structures with high man-
nose content [28].
Aah VI is the ¢rst glycosylated scorpion neurotoxin to be
characterised. The characteristic consensus sequence NX(T/S)
for a glycosylation site has, however, already been found in
other toxins from Old World scorpions. For example, the
NCT 11^13 sequence is present in the much studied Aah II
toxin [29]. However, the involvement of Cys-12 in a disulphide
bridge probably prevents glycosylation from occurring. The
consensus sequences N(K/H/L)S at positions 7^9 and/or
NK(S/T) at positions 61^63 are found in some New World
toxins, but these toxins have never been reported to be glyco-
sylated. It would be of value to systematically measure the
precise molecular mass of newly characterised toxins, and
also of other not so recently discovered toxins, especially
those containing a potential glycosylation site, because other
recently puri¢ed scorpion toxins have been found, by mass
spectrometry, to be heterogeneously glycosylated (M. Alami,
personal communication).
As far as we know, no glycosylated animal toxin with a size
similar to that of Aah VI has been reported in the literature.
The PLA2 from honey bee venom is not toxic, whereas the
toxic PLA2 isolated from the Australian tiger snake (Notechis
scutatus scutatus) was reported to be not glycosylated [30].
The toxic protein physalitoxin, from the venom of Physalia
physalis, appears to be responsible for both the haemolytic
and lethal activities of the venom [31], but its molecular
mass is far higher than that of Aah VI. Thus, there is no
actual glycosylated animal toxic protein to which Aah VI
can be compared.
The resistance of Aah VI to complete deglycosylation
should be further investigated to check whether this glycosy-
lation motif contributes to the toxin activity. Note that Aah
STR1, which has a sequence which is 88% identical to that of
Aah VI, has no known activity. Aah VI may be the ¢rst
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member of a new class of toxins with original mode of action
and biological e¡ect.
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